Effect of n-3 PUFA supplementation at different EPA:DHA ratios on the spontaneously hypertensive obese rat model of the metabolic syndrome

Br J Nutr. 2015 Mar 28;113(6):878-87. doi: 10.1017/S0007114514004437. Epub 2015 Feb 27.

Abstract

The increasing incidence of the metabolic syndrome (MetS), a combination of risk factors before the onset of CVD and type 2 diabetes, encourages studies on the role of functional food components such as long-chain n-3 PUFA as preventive agents. In the present study, we explore the effect of EPA and DHA supplementation in different proportions on spontaneously hypertensive obese (SHROB) rats, a model for the MetS in a prediabetic state with mild oxidative stress. SHROB rats were randomised into four groups (n 7), each supplemented with EPA/DHA at ratios of 1:1, 2:1 and 1:2, or soyabean oil as the control for 13 weeks. The results showed that in all the proportions tested, EPA/DHA supplementation significantly lowered total and LDL-cholesterol concentrations, compared with those of the control group. EPA/DHA supplementation at the ratios of 1:1 and 2:1 significantly decreased inflammation (C-reactive protein levels) and lowered oxidative stress (decreased excretion of urinary isoprostanes), mainly at the ratio of 1:2. The activity of antioxidant enzymes increased in erythrocytes, abdominal fat and kidneys, with magnitudes depending on the EPA:DHA ratio. PUFA mixtures from fish affected different MetS markers of CVD risk factors in SHROB rats, depending on the ratios of EPA/DHA supplementation. The activation of endogenous defence systems may be related to the reduction of inflammation and oxidative stress.

Keywords: EPA/DHA.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abdominal Fat / enzymology
  • Abdominal Fat / immunology
  • Abdominal Fat / metabolism
  • Animals
  • Biomarkers / blood
  • Biomarkers / metabolism
  • Biomarkers / urine
  • C-Reactive Protein / analysis
  • Dietary Supplements*
  • Docosahexaenoic Acids / administration & dosage
  • Docosahexaenoic Acids / therapeutic use*
  • Eicosapentaenoic Acid / administration & dosage
  • Eicosapentaenoic Acid / therapeutic use*
  • Erythrocytes / enzymology
  • Erythrocytes / immunology
  • Erythrocytes / metabolism
  • Female
  • Fish Oils / administration & dosage
  • Fish Oils / therapeutic use
  • Hypercholesterolemia / etiology
  • Hypercholesterolemia / prevention & control
  • Hypertension / etiology
  • Hypertension / prevention & control*
  • Kidney / enzymology
  • Kidney / immunology
  • Kidney / metabolism
  • Metabolic Syndrome / complications
  • Metabolic Syndrome / diet therapy*
  • Metabolic Syndrome / immunology
  • Metabolic Syndrome / physiopathology
  • Obesity / complications*
  • Oxidative Stress
  • Oxidoreductases / blood
  • Oxidoreductases / metabolism
  • Prediabetic State / etiology
  • Prediabetic State / prevention & control*
  • Random Allocation
  • Rats, Mutant Strains

Substances

  • Biomarkers
  • Fish Oils
  • Docosahexaenoic Acids
  • C-Reactive Protein
  • Eicosapentaenoic Acid
  • Oxidoreductases